Investors Heavily Search Novo Nordisk A/S (NVO): Here is What You Need to Know

Core Viewpoint - Novo Nordisk has been trending in stock searches, with recent performance showing a +4.4% return over the past month, outperforming the S&P 500's +2.7% and the Large Cap Pharmaceuticals industry's +3.5% [1] Earnings Estimate Revisions - The change in earnings projections is crucial for determining stock fair value, with upward revisions leading to increased stock prices [2] - Novo Nordisk is expected to report earnings of $0.81 per share for the current quarter, reflecting a +28.6% year-over-year change, although the Zacks Consensus Estimate has decreased by -0.9% over the last 30 days [3] - For the current fiscal year, the consensus earnings estimate is $3.41, indicating a +26.3% change from the previous year, with a slight decrease of -0.4% in the estimate over the last month [3] - The next fiscal year's consensus earnings estimate is $4.30, also showing a +26.3% change year-over-year, with a -0.6% change in the estimate over the past month [3] Revenue Growth Projections - The consensus sales estimate for the current quarter is $9.86 billion, representing a +24.3% year-over-year change [5] - For the current fiscal year, the sales estimate is $42.19 billion, indicating a +25.1% change, while the next fiscal year's estimate is $52.55 billion, reflecting a +24.6% change [5] Last Reported Results and Surprise History - In the last reported quarter, Novo Nordisk achieved revenues of $9.52 billion, a +23.7% year-over-year increase, and an EPS of $0.83 compared to $0.64 a year ago [6] - The reported revenues exceeded the Zacks Consensus Estimate of $9.23 billion by +3.15%, with an EPS surprise of +7.79% [6] - Over the last four quarters, Novo Nordisk surpassed consensus EPS estimates three times and revenue estimates two times [7] Valuation - Valuation is essential for investment decisions, comparing current valuation multiples like P/E, P/S, and P/CF against historical values and peers [8] - Novo Nordisk has a Zacks Value Style Score of D, indicating it is trading at a premium compared to its peers [9] Bottom Line - The information provided may assist in evaluating the market interest in Novo Nordisk, with a Zacks Rank of 3 suggesting it may perform in line with the broader market in the near term [10]